Peptides DB
Research-centric peptide and protocol reference hub
Study 8 of 15Pasireotide literatureEndocrine · Observational2026

Pasireotide induces proteins related to autophagy in cancer cells.

Pasireotide induces the expression of autophagy-related proteins in cancer cells, but the clinical relevance of these findings is unclear without further studies.

Read at EndocrineAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
10
Observational · this one
0
Open-label
0
Randomised
4
Reviews

Summary and findings

This study investigated the effects of Pasireotide (PAS) on autophagy-related proteins in MDA-MB-468 and HeLa cancer cells. The cells were exposed to PAS or a vehicle control for 8, 24, and 32 hours. The findings indicated that PAS treatment induced the expression of several autophagy-related proteins.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Endocrine supplied them

<h4>Purpose</h4>To investigate the possibility that Pasireotide (PAS), which is a synthetic somatostatin analog (SSA), induces proteins related to autophagy in cancer cells.<h4>Methods</h4>MDA-MB-468 and HeLa human cancer cells were exposed to PAS or vehicle for 8, 24 and 32 h, to assess possible effects in autophagy-related proteins. Western blot analysis was utilized to assess changes in protein expression levels due to PAS exposure.<h4>Results</h4>PAS treatment induces the expression of the autophagy-related protein (ATG)-3, ATG-7, and Beclin-1 in MDA-MB-468 and HeLa cells.<h4>Conclusions</h4>Our findings suggest that the beneficial effects of PAS in cancers may involve autophagy. Further studies will attempt to elucidate the underlying mechanisms mediating those effects.

Background

This paper addresses the role of Pasireotide, a synthetic somatostatin analog, in inducing autophagy-related proteins in cancer cells. Previous research has indicated that autophagy may play a role in cancer progression and treatment responses. Understanding how PAS influences autophagy could provide insights into its potential mechanisms of action in cancer therapy.

Methods

The study utilized MDA-MB-468 and HeLa human cancer cell lines, exposing them to Pasireotide or a vehicle control for durations of 8, 24, and 32 hours. The primary outcome measure was the expression of autophagy-related proteins assessed through Western blot analysis.

Results

The study reports that Pasireotide treatment induces the expression of autophagy-related proteins ATG-3, ATG-7, and Beclin-1 in both MDA-MB-468 and HeLa cells. Specific numeric findings regarding the extent of these changes were not reported.

Interpretation

While the findings suggest that Pasireotide may influence autophagy in cancer cells, the lack of quantitative data limits the ability to assess the clinical significance of these effects. The results should be interpreted cautiously, as they do not provide direct evidence of therapeutic benefit or mechanism. Further studies are necessary to determine the relevance of these findings in clinical settings.

Key findings

  • Induced expression of ATG-3 in MDA-MB-468 and HeLa cells.
  • Induced expression of ATG-7 in MDA-MB-468 and HeLa cells.
  • Induced expression of Beclin-1 in MDA-MB-468 and HeLa cells.

Limitations

  • No quantitative data reported.
  • Lack of clinical outcomes.
  • In vitro study, results may not translate to clinical settings.
  • Short exposure times may not reflect long-term effects.

Elsewhere in the Pasireotide corpus

BGH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.Pituitary · 2026 · n=65 · Not reported in abstract.HumanBManagement and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature.Endocrine · 2026 · n=120 · Symptom worsening occurred in 16.7-40%.reviewBMulti-Layered Molecular Profiling Informs the Diagnosis and Targeted Therapy of Desmoplastic Small Round Cell Tumorbiorxiv-preprint · 2025 · 62% disease control rate among patients receiving recommended therapies.HumanCHypothalamic deiodinase type-3 establishes the period of circannual interval timing in mammalsbiorxiv-preprint · 2025 · Not reported in abstract.AnimalBPrevalence, comorbidities and treatment outcomes of patients with Acromegaly in Qatar. Running title: Acromegaly in Qatarbiorxiv-preprint · 2025 · 1.90 per 100,000 (95% CI: 1.41–2.39)HumanDComparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysisbiorxiv-preprint · 2025 · Pasireotide showed a mean difference of -331 (95% CI: -1.75e+03, 1.09e+03) in 24-hour urinary free cortisol reduction.review